浙江东亚药业股份有限公司第四届董事会第十四次会议决议公告

Group 1 - The fourth meeting of the board of directors of Zhejiang East Asia Pharmaceutical Co., Ltd. was held on February 6, 2026, with all seven directors present, complying with relevant laws and regulations [2][3]. - The board approved the election of Wang Sheng as a member of the strategic committee, ensuring the normal operation of the committee [3][4]. - The board also approved the revision of the company's seal management system, with unanimous support from all directors [5][4]. Group 2 - The board approved the repurchase and cancellation of 6,000 shares of restricted stock from an incentive object who has left the company, with a repurchase price of 9.47 yuan per share plus applicable interest [6][32]. - The total number of shares to be repurchased represents 0.28% of the total shares granted under the incentive plan and 0.0052% of the company's total share capital [39][32]. - The repurchase will reduce the company's total share capital from 114,726,119 shares to 114,720,119 shares [12][39]. Group 3 - The board approved an increase in the maximum amount for entrusted financial management from 250 million yuan to 300 million yuan, with the same investment period ending on December 8, 2026 [19][20]. - The purpose of this adjustment is to improve the efficiency of the company's idle funds while ensuring daily operational needs and safety [28][20]. - The company will select reputable financial institutions for the entrusted management of funds, focusing on low-risk financial products [20][28].